MSQ Health

msqhealth.com

MSQ Health Group is a proudly South African healthcare company that offers innovative integrated solutions that improve patient management and address the needs of the African market. We believe that universal access to quality health products is a right for every patient and through innovation, we can improve healthcare and bring new technologies to the market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma | May 04, 2021

news image

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More

DIAGNOSTICS

EXOTHERA ANNOUNCES INDUSTRIAL SCALE AAV MANUFACTURING COLLABORATION WITH LOGICBIO THERAPEUTICS AND POLYPLUS

Exothera | June 15, 2022

news image

Exothera SA today announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L. Adeno-associated viruses (AAV) are non-enveloped, non-pathogenic viruses largely used as drug delivery vectors for biotherapeutics, like gene therapies and vaccines. Although the application of AAV is spreading rapidly, the industry is struggling to find cost-effecti...

Read More

NEUROPORE THERAPIES RECEIVES $500,000 GRANT FROM THE ALS ASSOCIATION

BioSpace | February 17, 2020

news image

Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of neurodegenerative disorders, announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Devel...

Read More

INDUSTRY OUTLOOK

TANTU AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ENGINEER A LIVING BIOTHERAPEUTIC FOR GASTROINTESTINAL HEALING

Ginkgo Bioworks | September 07, 2021

news image

Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the research and development of Tantu's therapeutic genes. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp., serves customers across industries seeking to develop new and better products using biology. Ta...

Read More
news image

INDUSTRIAL IMPACT

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma | May 04, 2021

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More
news image

DIAGNOSTICS

EXOTHERA ANNOUNCES INDUSTRIAL SCALE AAV MANUFACTURING COLLABORATION WITH LOGICBIO THERAPEUTICS AND POLYPLUS

Exothera | June 15, 2022

Exothera SA today announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L. Adeno-associated viruses (AAV) are non-enveloped, non-pathogenic viruses largely used as drug delivery vectors for biotherapeutics, like gene therapies and vaccines. Although the application of AAV is spreading rapidly, the industry is struggling to find cost-effecti...

Read More
news image

NEUROPORE THERAPIES RECEIVES $500,000 GRANT FROM THE ALS ASSOCIATION

BioSpace | February 17, 2020

Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of neurodegenerative disorders, announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Devel...

Read More
news image

INDUSTRY OUTLOOK

TANTU AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ENGINEER A LIVING BIOTHERAPEUTIC FOR GASTROINTESTINAL HEALING

Ginkgo Bioworks | September 07, 2021

Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the research and development of Tantu's therapeutic genes. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp., serves customers across industries seeking to develop new and better products using biology. Ta...

Read More